Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: S01EE01

Catiolanze(Latanoprost)

Glaucoma, Open-Angle

Marketing Authorisation Holder: Santen Oy

EMA Authorisation: 15/11/2023

INN: latanoprost

Indication

Catiolanze is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension. Catiolanze is indicated for the reduction of elevated IOP in children from 4 years of age and adolescents with elevated IOP and paediatric glaucoma.  

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Catiolanze — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.